key: cord-0898070-htpyn9ve
authors: Pape, Kathryn A.; Dileepan, Thamotharampillai; Kabage, Amanda J.; Kozysa, Daria; Batres, Rodolfo; Evert, Clayton; Matson, Michael; Lopez, Sharon; Krueger, Peter D.; Graiziger, Carolyn; Vaughn, Byron P.; Shmidt, Eugenia; Rhein, Joshua; Schacker, Timothy W.; Khoruts, Alexander; Jenkins, Marc K.
title: High affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines
date: 2021-09-25
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109823
sha: b1c3a0ddab28f99929550345d3bd75847a0d676f
doc_id: 898070
cord_uid: htpyn9ve

While both infections and vaccines induce memory B cell (MBC) populations that participate in secondary immune responses, the MBCs generated in each case can differ. Here we compare SARS-CoV-2 spike receptor binding domain (S1-RBD)-specific primary MBCs that form in response to infection or a single mRNA vaccination. Both primary MBC populations have similar frequencies in the blood, and respond to a second S1-RBD exposure by rapidly producing plasmablasts with an abundant IgA+ subset, and secondary MBCs that are mostly IgG+ and cross-react on the B.1.351 variant. However, infection-induced primary MBCs have better antigen-binding capacity and generate more plasmablasts and secondary MBCs of the classical and atypical subsets than vaccine-induced primary MBCs. Our results suggest that infection-induced primary MBCs have undergone more affinity maturation than vaccine-induced primary MBCs and produce more robust secondary responses.

J o u r n a l P r e -p r o o f INTRODUCTION mRNA vaccines encoding the SARS-CoV-2 (CoV2) spike protein potently induce antibodies, some capable of neutralizing the virus, and afford protective immunity from infection (Goel et al., 2021; Pascolo, 2021; Polack et al., 2020; Widge et al., 2021) . The antigenic simplicity of these vaccines and their administration to millions of immunologically naïve people provides an unprecedented opportunity to study the dynamics, activation, and differentiation of antigenspecific B cells in humans.

Studies of mice indicate that the B cell response to protein antigens in naïve individuals is initiated when rare naïve B cells expressing surface immunoglobulin (Ig) bind the antigen in secondary lymphoid organs, receive signals from helper T cells, and proliferate (McHeyzer-Williams and McHeyzer-Williams, 2005) . This proliferation produces short-lived Ig-secreting plasmablasts and non-plasmablasts that either become germinal center cells or germinal centerindependent memory cells that usually express IgM. The germinal center cells switch their Ig constant region from IgM to IgG, IgA, or IgE and acquire somatic mutations in the variable region, some of which improve antigen binding and allow the cells to survive the germinal center reaction as long-lived switched Ig (swIg) + memory cells or surface Igplasma cells that maintain serum Ig levels (Mesin et al., 2016; Nutt et al., 2015; Tarlinton, 2008) . After subsequent exposure to antigen, the memory cells proliferate rapidly and generate plasmablasts, which boost the amount of antigen-specific Ig in the serum to aid in antigen clearance, or to a lesser extent become germinal center cells to generate new memory cells with additional Ig mutations (Inoue et al., 2018; Pape et al., 2011; Suan et al., 2017) .

In humans, the non-plasmablast population contains CD21 + classical memory B cells (cl-MBC), and 2 poorly understood subsetsa CD21 -CD27 + population that contains a plasmablast-like subset and is sometimes referred to as the activated B cell population (Ellebedy et al., 2016; Louis et al., 2021) but will be referred to here as pb-MBC, and a CD21 -CD27population that is referred to as atypical memory B cells (at-MBC) and contains a CD11c + subset that shares features with an atypical B cell population in aged mice (Hao et al., 2011; Rubtsova et al., 2013; Wang et al., 2018) . These at-MBCs, which express T-bet and may be recent products of germinal centers (Lau et al., 2017) , are prominent in autoimmunity and chronic infection in humans (Isnardi et al., 2010; Jenks et al., 2020; Moir et al., 2008; Wei et al., 2007; Weiss et al., 2009 ), but can also be induced by vaccines (Andrews et al., 2019; Johnson et al., 2020; Kim et al., 2019; Sutton et al., 2021) . The mechanisms that generate the different MBC subsets are unclear. at-MBCs are particularly enigmatic as evidenced by conflicting studies on their life span, capacity for antibody production, and sensitivity to toll-like receptor signaling (Muellenbeck et al., 2013; Obeng-Adjei et al., 2017; Perez-Mazliah et al., 2018; Portugal et al., 2015; Rubtsov et al., 2011; Traore et al., 2009; Wong and Bhattacharya, 2019) .

Although germinal center cells are mainly restricted to secondary lymphoid organs (Blink et al., 2005) , plasmablasts and MBCs enter the blood and are therefore accessible for study in humans (Ellebedy et al., 2016) . Here, we took advantage of CoV2 mRNA vaccines to study the potential of human memory B cells generated by vaccination or infection. Our results indicate that primary MBCs formed in response to CoV2 infection have a higher antigen-binding capacity per cell and are more efficient at producing plasmablasts and MBCs during secondary immune responses than primary MBCs formed in response to mRNA vaccination.

J o u r n a l P r e -p r o o f cell population from naïve mice contained S1-RBD-specific cells that bound to S1-RBD/SA-AF647 but not the SA-PE-AF647 decoy, and a larger number of SA-, PE-, or AF647-specific cells that bound to SA-PE-AF647 but not S1-RBD/SA-AF647 (Fig. S1B) . The S1-RBD-specific B cells expressed IgM and IgD but lacked swIg as expected for naïve cells from the pre-immune repertoire (Cyster and Allen, 2019) . In contrast, mice immunized with S1-RBD in complete

Freund's adjuvant contained a larger number of S1-RBD-specific B cells and many were swIg + (Fig. S1C) . The fact that a small population of naïve-phenotype B cells was detected in unimmunized mice and a larger population of activated B cells in immunized mice is evidence that the B cells that bind the S1-RBD tetramer but not the decoy do so via S1-RBD-specific surface Ig receptors (BCRs).

A similar strategy was used to identify S1-RBD-specific B cells in the blood of human

volunteers. An example of the gating strategy is shown in Fig. S2 for a subject who received an mRNA vaccine 14 days earlier. The S1-RBD/SA-AF647 tetramer and the decoy fluorochrome SA-PE-AF647 were mixed with peripheral blood mononuclear cells before enrichment using magnetic beads conjugated with AF647 antibodies. The bound and unbound fractions from the magnetized columns were then stained with fluorochrome-labeled antibodies specific for markers of interest and gated for viable single cells with the light scatter properties of lymphocytes that did not express CD3, CD14, or CD16 ( Fig. S2A-C) . B cells were identified in this population based on expression of CD19 (Fig. S2D ) and S1-RBD-specific B cells were J o u r n a l P r e -p r o o f identified as cells that bound the S1-RBD but not the decoy tetramer (Fig. S2E) . The S1-RBDspecific B cells were further divided into CD19 lo CD20plasmablasts (Sanz et al., 2019) that also expressed CD27 and CD38, and CD19 + CD20 + non-plasmablasts that were CD38 lo (Fig. S2F ). S1-RBD tetramer-binding cells were only present in the unbound fraction from samples that contained large numbers of plasmablasts ( Fig. S2E-F and 1D) . These cells bound a low amount of S1-RBD tetramer likely due to reduced expression of surface Ig (Ellebedy et al., 2016) .

We first used this approach to detect S1-RBD-specific B cells in the blood of unvaccinated subjects ages 21-65 who had not had a previous CoV2 infection (CoV2-naïve) as evidenced by the lack of S1-RBD antibodies (Fig. 1A) . The magnetized column-bound fraction but not the unbound fraction from these individuals contained a few S1-RBD-specific B cells (Fig. 1B) that were present at an average frequency of 10 per million total B cells (Fig. 1C) . The S1-RBD tetramer-binding population contained 92 ± 10 % (mean ± SD, n = 11) non-plasmablasts, 80 ± 15 % expressing IgM and IgD, and most expressing CD21 but not the classical MBC marker CD27 ( Fig. 1B) . Thus, S1-RBD tetramer-binding cells were rare in pre-vaccination CoV2-naive subjects and most had the phenotype of naïve follicular B cells.

We then measured the response of the S1-RBD-specific naïve B cell population after CoV2naïve subjects received their first dose of the Pfizer or Moderna mRNA vaccines. The S1-RBD tetramer-binding cells retained the naïve phenotype and remained around 10 per million on postvaccination days 6-10 but increased to 385 per million on days 12-16 (Fig. 1C ). Plasmablasts accounted for much of the expanded population (Fig. 1D, 1E ) and on average were 17 ± 16

(mean ± SD, n = 23) % IgM + , 31 ± 21 % IgA + , and 48 ± 20 % IgG + . The increase in plasmablasts J o u r n a l P r e -p r o o f preceded an increase in S1-RBD antibodies on day 21-28 ( Fig. 1A) . The plasmablasts declined significantly to 5 cells per million by days 21-28 as expected for this short-lived cell type (Sze et al., 2000) (Fig. 1E ). S1-RBD tetramer-binding non-plasmablasts increased to a frequency of about 50 per million on days 12-16 and 62 per million at the time of the second vaccination on days 21-28 (Fig. 1D, 1F ). For the purposes of this study, the memory phase is considered to begin on day 21 as this is when MBCs achieve the same frequency in the blood as the secondary lymphoid organs where they are generated (Blink et al., 2005) . Non-plasmablasts in CoV2-naive subjects on days 21-28 after their first vaccination will therefore be referred to as vaccine-induced primary MBC. Many of these cells expressed CD27, a common marker of human MBCs (Sanz et al., 2019) , and tended to bind a bit more of the decoy reagent than naïve S1-RBD-specific B cells ( Fig. 2A ).

In summary, rare S1-RBD-specific naïve B cells proliferated after mRNA vaccination to form a large population of transient plasmablasts and a smaller population of primary MBCs that persisted in the blood until the time of the booster vaccination 3-4 weeks later.

We then assessed the secondary immune response to the booster dose of mRNA vaccine in CoV2-naïve subjects. In contrast to the primary response, which peaked on days 12-16 and generated 271 S1-RBD-specific plasmablasts per million (1E), the secondary S1-RBD-specific plasmablast response peaked at 828 cells per million on days 5-10 after booster vaccination, before declining by days 11-18 ( Fig. 2C-2D ). As expected, the secondary plasmablast response J o u r n a l P r e -p r o o f was accompanied by a boost in S1-RBD-specific antibodies (Fig. 1A) . Non-plasmablasts peaked at 266 cells per million on days 5-10, then fell to about 100 per million on days 11-18 and remained near that number on days 21-38 (Fig. 2B) . The non-plasmablasts present on day 21 and thereafter were defined as secondary MBCs. In summary, the booster vaccination generated a larger and more rapid plasmablast response than the primary, leaving subjects with 10-fold more S1-RBD-specific antibodies and 1.6 times more secondary MBCs than they had at the time of the boost.

The composition of the MBC populations changed during course of the booster vaccination.

Before the second vaccination, the S1-RBD-specific B cell population consisted of 62 nonplasmablasts ( Fig We then assessed the primary MBCs induced by CoV2 infection. People age 20-76 who had

CoV2 infections 2-9 months earlier, were recruited to the study and their prior infection was confirmed by assessment of S1-RBD antibodies. All of these individuals had antibodies, although the titers were slightly lower than those observed in CoV2-naive subjects after the first vaccination (Fig. 1A) . The S1-RBD-specific B population in CoV2-infected subjects consisted mostly of non-plasmablasts (Fig 2G) , which averaged 118 cells per million ( The secondary response in CoV2-infected individuals is more robust.

We then analyzed the secondary responses of people with prior CoV2 infection. CoV2-infected subjects generated a rapid secondary response on days 5-10 after their first vaccination, like the CoV2-naïve subjects did in response to their second vaccination. However, S1-RBD-specific secondary plasmablasts peaked at 5,117 cells per million on days 5-10 ( Fig. 2C , 2G), 6-fold J o u r n a l P r e -p r o o f higher than that observed in CoV2-naive subjects, before declining to 9 cells per million on days 11-18 (Fig. 2C, 2G ). The burst of plasmablasts coincided with a 30-fold increase in S1-RBDspecific antibodies (Fig. 1A) , which also was greater than the 10-fold increase in CoV2-naive subjects after their second vaccination.

Non-plasmablasts increased from 118 cells per million at the time of vaccination to 512 cells per million on days 5-10, which was not significantly different from the 266 cells per million generated during the secondary response in CoV2-naive subjects (Fig. 2B) . However, the secondary non-plasmablasts in CoV2-infected subjects remained stable at 625 and 614 cells per million, respectively, on days 11-18 and 21-38 ( Fig. 2B , 2G), in contrast to a 2-3-fold decline in

CoV-naive subjects. Thus, the secondary response to mRNA vaccination in CoV2-infected subjects generated 6-fold more secondary MBCs than the secondary response in CoV2-naive subjects.

We also examined the composition of the secondary MBCs in CoV2-infected subjects to determine which subsets were elevated over those in CoV2 naive subjects. On days 21-38 after vaccination, the secondary MBCs in CoV2-infected subjects contained 230 cl-MBCs, 70 pb-MBCs, and 164 at-MBCs per million, compared to 47 cl-MBCs, 23 pb-MBCs, and 13 at-MBCs per million in CoV2-naive subjects after their second dose of the vaccine (Fig. 2D-F) . Thus, the secondary response to single mRNA vaccination in CoV2-infected subjects generated 5-, 3-and 12-fold more cl-MBCs, pb-MBCs, and at-MBCs, respectively, than the secondary response in Ig affinity is thought to be critical for antigen neutralization (Kepler et al., 2014; Scheid et al., 2009 ). We therefore measured the relative affinities of the S1-RBD specific B cell populations.

The mean fluorescence intensity of S1-RBD tetramer bound per cell was divided by that of CD79b, a component of the BCR complex that is proportional to the amount of Ig on the cell surface, to normalize antigen binding to the levels of surface BCR. As illustrated by examples in Fig. 4A and 4B, this assay revealed that IgM + cells early in the primary response ( Fig. 4A ) bind less S1-RBD than IgG + MBC (Fig. 4B ). Our previous studies of antigen-specific B cells in mice showed that this difference is due to increased BCR affinity for antigen in the latter population and correlates with numerous somatic mutations (Pape et al., 2018) .

The IgM + IgD + S1-RBD tetramer-binding naïve cells from pre-vaccination CoV2-naive subjects, which presumably expressed un-mutated germ line-encoded Igs (Cyster and Allen, 2019), had a mean S1-RBD tetramer/CD79b ratio of 2.1 (Fig. 4C ). This ratio increased to 3.1 for the S1-RBD tetramer-binding swIg + non-plasmablast population present on days 11-18 and to 3.8 for the primary MBC population on days 21-28 at the time of the second vaccination (Fig. 4C ). The secondary MBCs present on days 21-38 after the second vaccination had a ratio of 4.7. Thus, there was a progressive increase in antigen-binding capacity with time after vaccination from the precursor IgM + and IgD + naïve cells to switched primary and then secondary MBCs, consistent with progressive affinity maturation. Furthermore, the detection of precursor IgM + and IgD + naïve S1-RBD-specific B cells, that likely do not have somatic mutations/affinity maturation, validates the sensitivity of the antigen-enrichment method used in this study.

The CoV2-induced primary MBC population had an S1-RBD tetramer/CD79b ratio of 7.1 before vaccination and it did not increase in the secondary MBC population induced by the first vaccination ( Fig. 4C ).

We also assessed the tertiary response of CoV2-infected subjects to their second vaccination. which was about 20-fold fewer plasmablasts than these subjects generated during the secondary response. The weak plasmablast response corresponded with the lack of an increase in S1-RBDspecific serum antibodies 2 weeks after the second vaccination ( Finally, these tertiary MBCs had similar S1-RBD tetramer/CD79b ratios to the secondary MBCs At this time, the S1-RBD-specific MBCs present in both the CoV2-infected and CoV2-naive individuals had similar S1-RBD tetramer/CD79b ratios (Fig. 4C ). We also determined whether the MBCs present in fully vaccinated CoV2-infected and CoV2-naive individuals bound to the S1-RBD from the B.1.351 variant (Khateeb et al., 2021) , which contains 3 amino acid substitutions compared to the wild-type S1-RBD in the vaccine. PBMCs were stained simultaneously with wild-type S1-RBD tetramer labeled with one fluorochrome and B.1.351 S1-RBD tetramer labeled with another ( Fig. 6A ). An average of 74% of the secondary MBCs from

CoV2-naïve subjects, and 62% from CoV2-infected subjects that bound to the wild-type S1-RBD also bound the B.1.351 S1-RBD (Fig. 6B ). In summary, even though both MBC populations present several months after the second vaccination had the same degree of affinity maturation and cross-reactivity on the B.1.351 variant, there were more cl-MBC and at-MBCs in individuals that had previous CoV2 infection.

The goal of this study was to characterize the secondary immune responses of MBC populations generated by an mRNA vaccine or CoV2 infection. Like most studies of adaptive immune J o u r n a l P r e -p r o o f responses in humans, our analysis was limited to the peripheral blood even though the S1-RBDspecific MBCs of interest were likely generated in secondary lymphoid organs and produced plasmablasts and secondary MBCs in this location during secondary responses. Other studies, however, have shown that primary MBCs have the same frequency in secondary lymphoid organs and blood by 3 weeks after immunization (Blink et al., 2005) and that plasmablasts generated from MBCs in secondary lymphoid organs rapidly enter the blood (Ellebedy et al., 2016) . Thus, our results for MBCs and their plasmablast progeny in blood are likely reflective of what occurred in the lymph nodes.

Our data indicate that CoV2-naïve people have a small number of phenotypically naïve B cells with BCRs with a relatively low capacity for S1-RBD binding. These features suggest that these B cells had not responded or undergone affinity maturation in response to common coronavirusesa conclusion that has also been reached from antibody studies (Sette and Crotty, 2021) . The primary MBCs that formed from these naïve precursors 3-4 weeks after the first mRNA vaccination in CoV2-naive people showed evidence of minimal affinity maturation, perhaps because not enough time had passed for the process to occur. Thus, increasing the time between the first and second injections of mRNA vaccines may be beneficial due to accumulation of MBCs with higher affinity BCRs during the expanded interval. We found evidence that the secondary MBCs underwent marked affinity maturation by 3-4 and especially 8-11 weeks after the second vaccination. This result indicates that mRNA vaccines are potent drivers of secondary germinal center B cell formation in CoV2-naive people and that this process can go on for weeks as suggested by the finding that spike-specific antibodies continue to accrue somatic mutations for 6 months after the second vaccination (Sokal et al., 2021; J o u r n a l P r e -p r o o f 2021). In contrast to the vaccine-induced primary MBCs, we found that CoV2-induced primary MBCs had undergone maximal affinity maturation even before vaccination, either because the inducing infection occurred many months in the past thereby allowing time for maximal accrual of somatic mutations, or because CoV2 infection is a stronger stimulus for affinity maturation than a single mRNA vaccination.

The S1-RBD specific primary MBC populations induced by mRNA vaccination or CoV2 infection had several similarities despite their different origins, ages, and antigen-binding capacities. They both contained similar numbers of cl-MBCs, pb-MBCs, and at-MBCs. Both populations generated CD21 -CD27 + secondary pb-MBCs that survived stably for several months. Thus, S1-RBD-specific pb-MBCs may be more than short-lived activated precursors fated to enter the cl-MBC pool (Ellebedy et al., 2016) , although it remains to be seen if they will eventually decline. Both populations, which had very few at-MBCs, generated this subset efficiently early in the secondary response. This finding adds to the growing literature showing that at-MBCs are generated after vaccination and thus may be unappreciated components of normal antigen-specific B cell responses in humans (Andrews et al., 2019; Johnson et al., 2020; Kim et al., 2019; Sutton et al., 2021; Weiss et al., 2009) .

Another similarity involved isotype switching. Although both the primary MBC populations induced by mRNA vaccination or CoV2 infection contained as many as 25% IgM + cells, they rapidly generated almost exclusively swIg + plasmablasts during the secondary response. This finding is consistent with earlier work showing that swIg + memory B cells are predisposed to produce plasmablasts much faster than naive B cells (Pape et al., 2011; Wrammert et al., 2008) J o u r n a l P r e -p r o o f and that IgM + memory B cells are inefficient contributors to secondary antibody responses (Pape et al., 2011) . In addition, while both MBC populations contained less than 5 % IgA + cells, 30 % of their plasmablast progeny expressed this isotype, consistent with a previous study of CoV2induced primary MBCs (Dan et al., 2021) . Assuming that IgA + memory cells do not proliferate more than other memory cells and IgM + memory cells do not contribute much to the secondary response, the most likely explanation for the abundance of IgA + plasmablasts is rapid switching of IgG + MBCs to IgA. Notably, secondary MBCs generated from the primary MBC populations contained less than 5 % IgA + cells, similar to their primary MBC precursors. The mechanism that prevents the efficient formation of IgA + MBCs is not known.

The primary MBC populations induced by mRNA vaccination or CoV2 infection, however, had several different behaviors during secondary responses to mRNA vaccination. The CoV2induced primary MBCs produced 6-fold more plasmablasts than the vaccine-induced MBCs, perhaps because their more affinity-matured BCRs transduced stronger signals. Strong BCR signaling has been shown in other contexts to favor the plasmablast fate (Pape et al., 2018; Paus et al., 2006) . Receipt of stronger BCR signals could also account for the finding that the affinity matured CoV2-induced primary MBC population produced secondary MBCs more efficiently than vaccine-induced primary MBCs, as other work indicates that B cells that receive strong BCR signals proliferate more and produce more apoptosis-resistant progeny than B cells that proliferate less (Taylor et al., 2015) . Strong BCR signaling may be particularly conducive to formation of the at-MBCs as these cells accumulate in situations of chronic antigenic stimulation (Isnardi et al., 2010; Jenks et al., 2020; Moir et al., 2008; Wei et al., 2007; Weiss et al., 2009 ).

Curiously, Andrews et al. (Andrews et al., 2019) observed that naïve B cells specific for the J o u r n a l P r e -p r o o f variable head region of influenza hemagglutinin formed at-MBCs more efficiently than MBCs specific for the conserved stem region in the same individuals. We wonder whether stem-specific antibodies from prior infections limit the available antigen for stem-specific MBCs, thereby reducing their BCR signaling and capacity to form at-MBCs.

Remarkably, the S1-RBD-specific secondary MBC population in CoV2-infected people produced few plasmablasts or tertiary MBCs after booster vaccination as described by Goel et al. 

The authors declare no competing interests.

We worked to ensure sex balance in the selection of non-human subjects. Such values were at or below the limit of detection. 

(A-E) Total log10 number of S1-RBD tetramer-binding total MBCs (A), plasmablasts (B), CD21 + cl-MBCs (C), CD21 -CD27 + pb-MBCs, (D), or CD21 -CD21 -CD11c + at-MBCs (E) per million total B cells in the peripheral blood of CoV2-naïve (black circles) or CoV2-infected (red circles) subjects (n = 5-12) at the indicated times after the second vaccination. Box and whisker plots are formatted as in Fig. 1C . Values were compared with one-way ANOVA. **** = p < 0.0001, * = p < 0.05, ns = not significant. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Marc K. Jenkins (jenki002@umn.edu).

Constructs used in this study such as pcDNA3.1-Zeo-S1-RBD-BirA construct and all unique materials are available from the lead contact under a materials transfer agreement (MTA).

Data and code availability  All data reported in this paper will be shared by the lead contact upon request.

 This paper does not report original code.

 Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Human participants (Table S1 ) that were CoV2-naive or had previous CoV2 infection were followed at the time of and up to 3 months after vaccination with Pfizer or Moderna mRNA vaccines. Severity of COVID-19 illness was rated using a 1-5 Likert scale that incorporated systemic, respiratory, and gastrointestinal symptoms (1 = minimal, i.e., carry on normal activities, mild discomfort, less than 1 week; 2 = mild, i.e., slightly decreased activities, mild discomfort, less than 2 weeks; 3 = moderate, i.e., significantly decreased activities, moderate discomfort; 4 = severe, i.e., significantly decreased activities, moderate to high discomfort, longer duration, no hospitalization; 5 = hospitalization).

Severity of side effects following immunization was rated using a 0-4 Likert scale (0 = no side effects except for arm pain or discomfort; 1 = minimal, i.e., carry on normal activities, mild J o u r n a l P r e -p r o o f discomfort; 2 = mild, i.e., slightly decreased activities, mild discomfort; 3 = moderate, i.e., significantly decreased activities, moderate discomfort; 4 = severe, i.e., ER visit and/or hospitalization. One of the participants with history of COVID-19 illness had severe symptoms (fevers, chest tightness) within 24 hours of his first dose of the Pfizer vaccine and did not receive a second dose.

The study protocol was reviewed and approved by an independent Institutional Review Board at supplemented with 10% Fetal Bovine Serum, L-Glutamine, HEPES buffer, Non Essential Amino Acids (NEAA), sodium pyruvate, penicillin/streptomycin, and gentamycin, and incubated in a humidified chamber at 10% C0 2 and 37°C.

J o u r n a l P r e -p r o o f S1 RBD tetramer and decoy production A wild-type S1-RBD-6xHis tagged protein was generated using a 753 base pair gene block, synthesized by GenScript, that included from 5' to 3', a HindIII site, a Kozak sequence, codons for native signal peptide, the S1-RBD sequence (Arg319-Phe541), a 6x Histidine tag, a stop codon and an XhoI site (aagcttgccaccatgttcgtcttcctggtcctgctgcctctggtctcctcacagtgcagggtgcagccaaccgagtctatcgtgcgctttccta atatcacaaacctgtgcccatttggcgaggtgttcaacgcaacccgcttcgccagcgtgtacgcctggaataggaagcggatcagcaactg cgtggccgactatagcgtgctgtacaactccgcctctttcagcacctttaagtgctatggcgtgtcccccacaaagctgaatgacctgtgcttt accaacgtctacgccgattctttcgtgatcaggggcgacgaggtgcgccagatcgcccccggccagacaggcaagatcgcagactacaa ttataagctgccagacgatttcaccggctgcgtgatcgcctggaacagcaacaatctggattccaaagtgggcggcaactacaattatctgta ccggctgtttagaaagagcaatctgaagcccttcgagagggacatctctacagaaatctaccaggccggcagcaccccttgcaatggcgtg gagggctttaactgttatttcccactccagtcctacggcttccagcccacaaacggcgtgggctatcagccttaccgcgtggtggtgctgagc tttgagctgctgcacgccccagcaacagtgtgcggccccaagaagtccaccaatctggtgaagaacaagtgcgtgaacttccaccaccac caccaccactaactcgag). The gene block was cloned into pcDNA3.1/Zeo (+) using HindIII/XhoI sites and the resulting plasmid was named pcDNA3.1-Zeo(+):S1-RBD.

To generate S1-RBD-BirA, a 210 base pair gene block was synthesized with overlapping residues on both 5' and 3' ends for infusion cloning, including from 5' to 3', codons encoding part of wild-type S1-RBD, a GGGGS linker, a 6x His tag, another GGGGS linker, the BirA sequence, and a stop codon between BsrGI and BlpI sites in the original pcDNA3.1-Zeo(+):S1-RBD-BirA construct using in-fusion cloning. The DNA constructs were transfected into 293T cells using Effectene (Qiagen, Cat# 301425). Fresh medium was added on the following day and the supernatant was harvested and pooled on days 3 and 5. S1-RBD-BirA proteins were purified using Ni ++ affinity chromatography using standard procedures and the elute was washed and concentrated on 10K

Amicon Ultra Centrifugal Filters (Millipore # UFC801008)

Wild type or B.1.351 S1-RBD, at a concentration of 2 mg/ml in 10 mM Tris HCl, pH 8 was biotinylated using the Bir A protein ligase kit (Avidity #BirA500). Free biotin was removed by centrifugation in a 10K Amicon Ultra Centrifugal Filter with 2 PBS washes containing 2% sodium azide. Tetramer was prepared by reacting 1,000 pmoles of S1 RBD-biotin with 250 pmoles of SA-AF647 that was added in 4 increments with 20-minute incubations between each addition. The tetramer was washed 2 times in a 100K Amicon Ultra 0.5 ml filter (Millipore J o u r n a l P r e -p r o o f #UFC510008) and to remove any unreacted SA-AF647 or protein and adjusted to a final concentration of 1 µM SA.

The SA-AF647 decoy was prepared by conjugating SA-PE to AF647 (Invitrogen) for 60 minutes at room temperature. The free AF647 was removed by centrifugation in a 100K Amicon Ultra 0.5 ml filter. The SA-PE-AF647 complex concentration was calculated by measuring the absorbance of PE at 565 nm, and the solution was adjusted to 1 μM. The SA-PE-AF647 complex was then incubated with a ten-fold molar excess of free biotin for 30 minutes at room temperature to block any free sites on SA. Calculation of total numbers of S1-RBD tetramer binding cells per million B cells

The total number of S1-RBD specific cells per sample was obtained by multiplying the frequency of tetramer-binding B cells by the total number of single, live, lymphocytes eluted from the enrichment columns (bound fraction). At time points where plasmablasts were present (day 11-18 of the primary response and day 5-9 of the secondary response) the flow through fractions contained S1-RBD-specific plasmablasts that did not bind to the columns due to their lower levels of BCR. For these time points, the total numbers of plasmablasts in the flow through was added to the total numbers in the bound to obtain the total number of S1-RBD specific cells per sample.

To calculate the total S1-RBD specific cells per million B cells, the total number of S1-RBD specific cells in the sample was divided by the total number of single, live, CD19 + B cells in the entire sample (bound and flow through) and multiplied by 1 million. The frequency of CD20negative plasmablasts and CD20 + non-plasmablasts was then multiplied by the total S1 RBD binding cells per million B cells to obtain the total plasmablasts and non-plasmablasts per million B cells. For the MBC subset and isotype analysis, the total number of S1 RBD-specific nonplasmablasts per million B cells was multiplied by the frequency of the subset of interest. In order for a sample to be used for the subset analysis it had to contain at least 40 S1-RBD tetramer-binding cells.

Plasma samples collected before vaccination, 21-28 days after the first vaccination, and then 14-30 days after the second vaccination from each subject were titrated in 96-well plates coated with 3 μg/ml S1-RBD in PBS and blocked with 1% BSA. Plate-bound Ig of all isotypes was detected by incubating the wells sequentially with horseradish peroxidase-labeled antibodies specific for human Ig heavy and light chains (Invitrogen/ThermoFisher #31412), and KPL ABTS Peroxidase Substrate (SeraCare #5120-0043). Each plate contained the same known positive and negative serum as a reference. The optical density (405 nm) of each well was measured in an ELISA plate reader. Titers were calculated as the reciprocal of the dilution that gave a half-maximal optical density (405) nm value.

Statistical significance between the log10 cell per million values or S1-RBD/CD79b MFI ratios for individual samples from different groups was analyzed by ordinary one-way ANOVA and

Sidak's multiple comparison tests using Prism version 9. The exact values of n are stated in the figure legends. Only samples that contained at least 40 S1-RBD tetramer-binding cells were included for analyses of MBC subsets. One value was excluded as described in the legend to Fig.   4 . CoV2-naive subjects CoV2-infected subjects S1-RBD decoy CD20 CD19 CD21 CD27 S1-RBD decoy CD20 CD19 CD21 CD27 A CD11c CD19 S1-RBD-specific B cells S1-RBD-specific nPB S1-RBD-specific CD21 -CD27 -nPB B cells Secondary day 28-33 G CD11c CD19 S1-RBD-specific B cells S1-RBD-specific nPB S1-RBD-specific CD21 -CD27 -nPB B cells CD11c CD19 CD11c CD19 CD11c CD19 S1-RBD decoy S1-RBD decoy CD20 CD19 CD20 CD19 CD21 CD27 CD21 CD27 CoV2-induced subjects Cov2-naive subjects S1-RBD-specific cells/10 6 (log10) S1-RBD-specific cells/10 6 (log10) S1-RBD-specific cells/10 6 (log10) S1-RBD-specific cells/10 6 (log10) S1-RBD-specific cells/10 6 (log10) S1-RBD-specific nPB S1-RBD-specific swIg + nPB S1-RBD-specific swIg + PB 99 52 S1-RBD-specific cells/10 6 (log10) S1-RBD-specific cells/10 6 (log10) S1-RBD-specific cells/10 6 (log10) S1-RBD-specific cells/10 6 (log10) Figure 5 CoV2-naive subjects CoV2-infected subjects lymphocytes and a side scatter area versus width profile of singlets (left two panels) that did not bind a cocktail of antibodies for B lineage negative markers, expressed immunoglobulin heavy and light chains, and were B220 + (right 2 panels). The cells expressing large amounts of intracellular Ig are plasmablasts. B cells from (B) naïve mice or (C) mice immunized with S1 RBD emulsified in CFA were enriched for S1-RBD-AF647 tetramer-binding cells.

The left contour plots show staining of decoy PE-AF647 versus S1-RBD-AF647 tetramer, with the percentages of cells binding S1-RBD-AF647 tetramer identified in the gate. The right contour plots show staining of IgM versus IgD, with percentages of S1 RBD tetramer-binding B cells that were IgM + IgD + and IgM -IgD -(swIg + ) identified by the gates. expressed CD19 (D). S1-RBD binding B cells were identified as B cells that expressed low amounts of decoy and bound the S1 RBD tetramer (E). The frequency of these cells are shown in the gate. Expression of CD19 versus CD20 (left plot) and CD27 versus CD38 (right plot) on the S1-RBD binding B cells was used identify CD19 lo CD20 -CD27 hi CD38 hi plasmablasts (red) and CD19 + CD20 + CD38 lo non-plasmablasts (blue) (F). The upper plots are cells from the S1-RBD-enriched sample, and the lower plots are cells from the portion of the sample that did not bind to the enrichment column. 

Activation dynamics and immunoglobulin evolution of pre-existing and newly generated human memory B cell responses to influenza hemagglutinin

Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization

B cell responses: Cell interaction dynamics and decisions

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination

A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice

Generation of memory B cells and their reactivation

Complement receptor 2/CD21-human naive B cells contain mostly autoreactive unresponsive clones

Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in Systemic Lupus Erythematosus

The transcription factor T-bet resolves memory B cell subsets with distinct tissue distributions and antibody specificities in mice and humans

Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies

Emerging SARS-CoV-2 variants of concern and potential intervention approaches

FCRL5(+) Memory B Cells Exhibit Robust Recall Responses

Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation

T-bet+CD27+CD21-B cells poised for plasma cell differentiation during antibody-mediated rejection of kidney transplants

First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19

Antigen-specific memory B cell development

Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals

Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies

The generation of antibody-secreting plasma cells

Malaria-induced interferon-gamma drives the expansion of Tbethi atypical memory B cells

Naive B cells with high-avidity germline-encoded antigen receptors produce persistent IgM(+) and transient IgG(+) memory B cells

Different B cell populations mediate early and late memory during an endogenous immune response

Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype

Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation

Plasmodium-specific atypical memory B cells are short-lived activated B cells

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity

T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

Maintenance of B-cell memory by long-lived cells generated from proliferating precursors

Human memory B cells

Adaptive immunity to SARS-CoV-2 and COVID-19

Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

mRNA vaccination boosts crossvariant neutralizing antibodies elicited by SARS-CoV-2 infection

Plasma cell and memory B cell differentiation from the germinal center

Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans

Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival

Evolution in miniature: selection, survival and distribution of antigen reactive cells in the germinal centre

Humoral immunity. Apoptosis and antigen affinity limit effector cell differentiation of a single naive B cell

The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali

IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c(hi)T-bet(+) B cells in SLE

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus

Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area

Durability of responses after SARS-CoV-2 mRNA-1273 vaccination

Basics of memory B-cell responses: lessons from and for the real world

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus